Ads
related to: psa testing nhs leaflet chart- Patient Characteristics
Learn About How Psoriatic Arthritis
Manifests Differently In Patients.
- Risk Of Treatment Delays
Learn How & Why Delay Can Lead To
Further Joint Damage Here.
- Clinical Trial Results
Get Results From A Clinical
Long-term Study Of A Biologic.
- IV Dosing Information
Learn More About IV Dosing &
Administration On The HCP Website.
- Mechanism Of Action
See How This Biologic Selectively
Targets And Blocks IL-17A.
- PsA Patient Support
Get Patients The Comprehensive
Support They Need With Our Plan.
- Patient Characteristics
Search results
Results From The WOW.Com Content Network
A further study, the NHS Comparison Arm for ProtecT (CAP), as part of the Prostate testing for cancer and Treatment (ProtecT) study, randomized GP practices with 460,000 men aged 50–69 at centers in 9 cities in Britain from 2001–2005 to usual care or prostate cancer screening with PSA (biopsy if PSA ≥ 3). [65]
Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), P-30 antigen, is a glycoprotein enzyme encoded in humans by the KLK3 gene.PSA is a member of the kallikrein-related peptidase family and is secreted by the epithelial cells of the prostate gland in men and the paraurethral glands in women.
Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder.Abnormal growth of the prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA) levels.
In men aged 55–69 who have been counseled on the known harms and potential benefits of prostate cancer screening, the U.S. Preventive Service Task Force May 2018 statement states, "The use of digital rectal examination as a screening modality is not recommended because there is a lack of evidence on the benefits."
Richard J. Ablin (May 15, 1940 – October 6, 2023) [1] was an American scientist, most notable for research on prostate cancer.According to the Wall Street Journal: . Richard Ablin, a professor of pathology at University of Arizona College of Medicine, discovered the prostate-specific antigen (PSA) in 1970, and for nearly as long, he has argued that it should not be used for routine screening.
PAP was used to monitor and assess progression of prostate cancer until the introduction of prostate specific antigen (PSA), which has now largely displaced it. Subsequent work, suggested that it has a role in prognosticating intermediate and high-risk prostate cancer, and led to renewed interest in it as a biomarker .
Ad
related to: psa testing nhs leaflet chart